Olanzapine + Fluoxetine + Placebo
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment Resistant Depression
Conditions
Treatment Resistant Depression
Trial Timeline
Sep 1, 2012 → Nov 1, 2015
NCT ID
NCT01687478About Olanzapine + Fluoxetine + Placebo
Olanzapine + Fluoxetine + Placebo is a phase 3 stage product being developed by Eli Lilly for Treatment Resistant Depression. The current trial status is terminated. This product is registered under clinical trial identifier NCT01687478. Target conditions include Treatment Resistant Depression.
What happened to similar drugs?
3 of 20 similar drugs in Treatment Resistant Depression were approved
Approved (3) Terminated (3) Active (14)
🔄HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate + nab-paclitaxel; gemcitabineJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01687478 | Phase 3 | Terminated |
Competing Products
20 competing products in Treatment Resistant Depression